All articles by Frankie Fattorini

Frankie Fattorini

Frankie Fattorini is a healthcare and pharmaceutical reporter. His background is in genomics research, and he has also worked in medical communications. Frankie has written freelance articles on emerging technologies and various pieces on oncology and drug development.

Podcast: Rare Disease Day: FDA guidance allowing advancement

It’s been a busy year for rare disease developers, with the US Food and Drug Administration (FDA) releasing several new…
Pharma eyes AI deals to stem lost revenues from patent expirations

Pharmaceutical giants are employing an array of tactics to minimise the falling revenues that come when patents expire on their…
Why pharma manufacturers are still investing in Europe

Undeterred by tariffs and global competition, pharma manufacturers are seeing an opportunity in Europe and continuing to invest accordingly. Europe’s…
JPM26: Fujifilm’s modular manufacturing answer to pharma tariffs

Fujifilm Biotechnology’s system of setting up similar manufacturing facilities across the globe —termed the ‘KojoX’ approach — has allowed the…
JPM26: Bayer evades patent cliff in a way it may not be able to repeat

Bayer is re-entering key assets in the US market under new indications to reclaim lost profits from patent expirations for…

JPM26: 2025 a “breakout year” for rare disease biotechs

Developers in rare disease emphasise cashflow and R&D expansion as evidence of their transition from emerging biotechs to established companies…
JPM26: GSK banks on recent AI deals to offset patent expiries

Early year artificial intelligence (AI) collaborations are helping form GSK’s “multimodal approach” to drug discovery, says CSO Tony Wood, strengthening…
JPM26: Vertex hopes to match cystic fibrosis success in pain and kidney disease

Vertex Pharmaceuticals is set to build upon its success cystic fibrosis (CF) and its potential blockbuster Casgevy through its non-opioid…
JPM26: BMS places confidence in core pipeline to weather 2030 patent cliff

Bristol Myers Squibb (BMS) is confident pivotal readouts from its core pipeline will drive profits towards 2030 despite looming patent…
FDA increases manufacturing flexibility for cell and gene therapies

The US Food and Drug Administration (FDA) has announced increased flexibility for cell and gene therapy (CGT) manufacturers, loosening quality…